Posted by Michael Wonder on 04 Sep 2023
Calquence approved in China for chronic lymphocytic leukaemia
4 September 2023 - Approval based on results from ASCEND global Phase III trial and a Phase I/II local trial, which showed 83.3% overall response rate in Chinese patients treated with Calquence.
AstraZeneca’s Calquence (acalabrutinib), a next generation, selective Bruton’s tyrosine kinase inhibitor, has been approved in China for the treatment of adult patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma who have received at least one prior therapy.
